C D Wyte1, W A Berk. 1. Department of Emergency Medicine, Detroit Receiving Hospital/University Health Center, Michigan 48201.
Abstract
STUDY OBJECTIVE: To evaluate the potential for cardiovascular toxicity from severe oral phenytoin overdose. STUDY POPULATION: Fifty-seven patients admitted during a two-year period to an inner-city hospital for severe oral phenytoin overdose, which is defined as a peak level of 40 micrograms/mL or more. METHODS: Case records were reviewed retrospectively for symptoms and signs of phenytoin toxicity, especially circulatory effects. Baseline and toxic 12-lead ECGs, when available, were reviewed in detail. Continuous variables were compared using either paired or unpaired t tests, as appropriate. Significance was taken as P less than or equal to .05. RESULTS: Mean peak phenytoin level was 49.4 +/- 7.7 micrograms/mL. Continuous single-lead ECG monitoring in 36 patients (63%) for a mean of 26.5 +/- 21.6 hours revealed no incidents of dysrhythmia requiring treatment. ECGs recorded during toxicity in 52 cases (91%) revealed no clinically significant abnormalities attributable to phenytoin. ECGs during toxic and baseline states were available for detailed analysis in 15 cases. Ten patients exhibited an increase in PR interval (mean, 19 +/- 10 ms) when toxic, whereas five had a decrease (mean, 18 +/- 11 ms) compared with nontoxic records. No change in heart rate, QRS duration, or corrected QT interval was observed. There were no circulatory complications and no deaths. CONCLUSION: Cardiovascular toxicity is rarely a manifestation of oral phenytoin overdose. Routine management of stable patients with severe phenytoin overdose in a monitored setting is not mandatory.
STUDY OBJECTIVE: To evaluate the potential for cardiovascular toxicity from severe oral phenytoinoverdose. STUDY POPULATION: Fifty-seven patients admitted during a two-year period to an inner-city hospital for severe oral phenytoinoverdose, which is defined as a peak level of 40 micrograms/mL or more. METHODS: Case records were reviewed retrospectively for symptoms and signs of phenytointoxicity, especially circulatory effects. Baseline and toxic 12-lead ECGs, when available, were reviewed in detail. Continuous variables were compared using either paired or unpaired t tests, as appropriate. Significance was taken as P less than or equal to .05. RESULTS: Mean peak phenytoin level was 49.4 +/- 7.7 micrograms/mL. Continuous single-lead ECG monitoring in 36 patients (63%) for a mean of 26.5 +/- 21.6 hours revealed no incidents of dysrhythmia requiring treatment. ECGs recorded during toxicity in 52 cases (91%) revealed no clinically significant abnormalities attributable to phenytoin. ECGs during toxic and baseline states were available for detailed analysis in 15 cases. Ten patients exhibited an increase in PR interval (mean, 19 +/- 10 ms) when toxic, whereas five had a decrease (mean, 18 +/- 11 ms) compared with nontoxic records. No change in heart rate, QRS duration, or corrected QT interval was observed. There were no circulatory complications and no deaths. CONCLUSION:Cardiovascular toxicity is rarely a manifestation of oral phenytoinoverdose. Routine management of stable patients with severe phenytoinoverdose in a monitored setting is not mandatory.
Authors: Rainer Schimpf; Christian Veltmann; Theano Papavassiliu; Boris Rudic; Turgay Göksu; Jürgen Kuschyk; Christian Wolpert; Charles Antzelevitch; Alois Ebner; Martin Borggrefe; Christian Brandt Journal: Heart Rhythm Date: 2012-01-11 Impact factor: 6.343